Association of Helicobacter pylori infection with complications of diabetes: a single-center retrospective study.
Humans
Helicobacter Infections
/ complications
Retrospective Studies
Male
Female
Middle Aged
Diabetes Mellitus, Type 2
/ complications
Helicobacter pylori
/ isolation & purification
Diabetic Nephropathies
/ epidemiology
Aged
Diabetes Complications
/ microbiology
Glycated Hemoglobin
/ analysis
Follow-Up Studies
Prognosis
Adult
Helicobacter pylori
Complication
Nephropathy
Type-2 diabetes
Journal
BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676
Informations de publication
Date de publication:
14 Aug 2024
14 Aug 2024
Historique:
received:
03
01
2024
accepted:
02
08
2024
medline:
14
8
2024
pubmed:
14
8
2024
entrez:
13
8
2024
Statut:
epublish
Résumé
Previous studies examined the association of Helicobacter pylori infection (H. pylori) with complications of diabetes, but the results have been inconsistent. The aim of this study of patients with type-2 diabetes (T2D) was to determine the association of H. pylori infection with the major complications of diabetes. This single-center retrospective study examined patients with T2D who received H. pylori testing between January 2016 and December 2021. Logistic regression analyses were used to evaluate the association of H. pylori infection with four major complications of diabetes. We examined 960 patients with T2D, and 481 of them (50.1%) were positive for H. pylori. H. pylori infection was significantly associated with diabetic nephropathy (odds ratio [OR] = 1.462; 95% confidence interval [CI]: 1.006,2.126; P = 0.046). In addition, the co-occurrence of H. pylori positivity with hypertension (OR = 4.451; 95% CI: 2.351,8.427; P < 0.001), with glycated hemoglobin A1c (HbA1c) of at least 8% (OR = 2.925; 95% CI: 1.544,5.541; P = 0.001), and with diabetes duration of at least 9 years (OR = 3.305; 95% CI:1.823,5.993; P < 0.001) further increased the risk of diabetic nephropathy. There was no evidence of an association of H. pylori infection with retinopathy, neuropathy, or peripheral vascular disease. Our study of T2D patients indicated that those with H. pylori infections had an increased risk of nephropathy, and this risk was greater in patients who also had hypertension, an HbA1c level of 8% or more, and diabetes duration of 9 years or more.
Sections du résumé
BACKGROUND
BACKGROUND
Previous studies examined the association of Helicobacter pylori infection (H. pylori) with complications of diabetes, but the results have been inconsistent. The aim of this study of patients with type-2 diabetes (T2D) was to determine the association of H. pylori infection with the major complications of diabetes.
METHODS
METHODS
This single-center retrospective study examined patients with T2D who received H. pylori testing between January 2016 and December 2021. Logistic regression analyses were used to evaluate the association of H. pylori infection with four major complications of diabetes.
RESULTS
RESULTS
We examined 960 patients with T2D, and 481 of them (50.1%) were positive for H. pylori. H. pylori infection was significantly associated with diabetic nephropathy (odds ratio [OR] = 1.462; 95% confidence interval [CI]: 1.006,2.126; P = 0.046). In addition, the co-occurrence of H. pylori positivity with hypertension (OR = 4.451; 95% CI: 2.351,8.427; P < 0.001), with glycated hemoglobin A1c (HbA1c) of at least 8% (OR = 2.925; 95% CI: 1.544,5.541; P = 0.001), and with diabetes duration of at least 9 years (OR = 3.305; 95% CI:1.823,5.993; P < 0.001) further increased the risk of diabetic nephropathy. There was no evidence of an association of H. pylori infection with retinopathy, neuropathy, or peripheral vascular disease.
CONCLUSIONS
CONCLUSIONS
Our study of T2D patients indicated that those with H. pylori infections had an increased risk of nephropathy, and this risk was greater in patients who also had hypertension, an HbA1c level of 8% or more, and diabetes duration of 9 years or more.
Identifiants
pubmed: 39138447
doi: 10.1186/s12902-024-01678-2
pii: 10.1186/s12902-024-01678-2
doi:
Substances chimiques
Glycated Hemoglobin
0
hemoglobin A1c protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
152Subventions
Organisme : This work was supported by the Top Talent of Changzhou "The 14th Five-Year Plan" High-Level Health Talents Training Project.
ID : 2022CZBJ051
Informations de copyright
© 2024. The Author(s).
Références
Martin-Nunez GM, Cornejo-Pareja I, Clemente-Postigo M, Tinahones FJ. Gut microbiota: the Missing Link between Helicobacter pylori infection and metabolic disorders? Front Endocrinol (Lausanne). 2021;12:639856. https://doi.org/10.3389/fendo.2021.639856 .
doi: 10.3389/fendo.2021.639856
pubmed: 34220702
Pellicano R, Ianiro G, Fagoonee S, Settanni CR, Gasbarrini A. Review: extragastric diseases and Helicobacter pylori. Helicobacter. 2020;25(Suppl 1):e12741. https://doi.org/10.1111/hel.12741 .
doi: 10.1111/hel.12741
pubmed: 32918343
Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81. https://doi.org/10.1016/j.diabres.2018.02.023 .
doi: 10.1016/j.diabres.2018.02.023
pubmed: 29496507
Faselis C, Katsimardou A, Imprialos K, Deligkaris P, Kallistratos M, Dimitriadis K. Microvascular complications of type 2 diabetes Mellitus. Curr Vasc Pharmacol. 2020;18(2):117–24. https://doi.org/10.2174/1570161117666190502103733 .
doi: 10.2174/1570161117666190502103733
pubmed: 31057114
Viigimaa M, Sachinidis A, Toumpourleka M, Koutsampasopoulos K, Alliksoo S, Titma T. Macrovascular complications of type 2 diabetes Mellitus. Curr Vasc Pharmacol. 2020;18(2):110–6. https://doi.org/10.2174/1570161117666190405165151 .
doi: 10.2174/1570161117666190405165151
pubmed: 30961498
Mansori K, Dehghanbanadaki H, Naderpour S, Rashti R, Moghaddam AB, Moradi Y. A systematic review and meta-analysis of the prevalence of Helicobacter pylori in patients with diabetes. Diabetes Metab Syndr. 2020;14(4):601–7. https://doi.org/10.1016/j.dsx.2020.05.009 .
doi: 10.1016/j.dsx.2020.05.009
pubmed: 32417710
Mansori K, Moradi Y, Naderpour S, Rashti R, Moghaddam AB, Saed L, et al. Helicobacter pylori infection as a risk factor for diabetes: a meta-analysis of case-control studies. BMC Gastroenterol. 2020;20(1):77. https://doi.org/10.1186/s12876-020-01223-0 .
doi: 10.1186/s12876-020-01223-0
pubmed: 32209055
pmcid: 7092473
Hsieh MC, Wang SS, Hsieh YT, Kuo FC, Soon MS, Wu DC. Helicobacter pylori infection associated with high HbA1c and type 2 diabetes. Eur J Clin Invest. 2013;43(9):949–56. https://doi.org/10.1111/eci.12124 .
doi: 10.1111/eci.12124
pubmed: 23879740
Chen J, Xing Y, Zhao L, Ma H. The Association between Helicobacter pylori Infection and glycated hemoglobin A in diabetes: a Meta-analysis. J Diabetes Res. 2019;2019:3705264. https://doi.org/10.1155/2019/3705264 .
doi: 10.1155/2019/3705264
pubmed: 31583248
pmcid: 6754895
Kim KJ, Choi J, Bae JH, Kim KJ, Yoo HJ, Seo JA, et al. Time to Reach Target Glycosylated Hemoglobin is Associated with long-term durable Glycemic Control and Risk of Diabetic complications in patients with newly diagnosed type 2 diabetes Mellitus: a 6-Year observational study. Diabetes Metab J. 2021;45(3):368–78. https://doi.org/10.4093/dmj.2020.0046 .
doi: 10.4093/dmj.2020.0046
pubmed: 33081424
Song X, Cai C, Jin Q, Chen X, Yu C. The efficacy of Helicobacter pylori eradication in diabetics and its effect on glycemic control: a systematic review and meta-analysis. Helicobacter. 2021;26(2):e12781. https://doi.org/10.1111/hel.12781 .
doi: 10.1111/hel.12781
pubmed: 33465265
Cheng KP, Yang YJ, Hung HC, Lin CH, Wu CT, Hung MH et al. Helicobacter pylori eradication improves glycemic control in type 2 diabetes patients with asymptomatic active Helicobacter pylori infection. J Diabetes Investig. 2019;10(4):1092 – 101.https://doi.org/0.1111/jdi.12991.
Kim WS, Choi Y, Kim N, Lim SH, Noh G, Kim KW, et al. Long-term effect of the eradication of Helicobacter pylori on the hemoglobin A1c in type 2 diabetes or prediabetes patients. Korean J Intern Med. 2022;37(3):579–90. https://doi.org/10.3904/kjim.2021.194 .
doi: 10.3904/kjim.2021.194
pubmed: 34991230
pmcid: 9082431
Demir M, Gokturk HS, Ozturk NA, Kulaksizoglu M, Serin E, Yilmaz U. Helicobacter pylori prevalence in diabetes mellitus patients with dyspeptic symptoms and its relationship to glycemic control and late complications. Dig Dis Sci. 2008;53(10):2646–9. https://doi.org/10.1007/s10620-007-0185-7 .
doi: 10.1007/s10620-007-0185-7
pubmed: 18320319
Kayar Y, Pamukcu O, Eroglu H, Kalkan Erol K, Ilhan A, Kocaman O. Relationship between Helicobacter pylori infections in Diabetic patients and inflammations, metabolic syndrome, and complications. Int J Chronic Dis. 2015;2015:290128. https://doi.org/10.1155/2015/290128 .
doi: 10.1155/2015/290128
pubmed: 26464868
pmcid: 4590934
Hamed SA, Amine NF, Galal GM, Helal SR, Tag El-Din LM, Shawky OA et al. Vascular risks and complications in diabetes mellitus: the role of helicobacter pylori infection. J Stroke Cerebrovasc Dis. 2008;17(2):86–94. https://doi.org/0.1016/j.jstrokecerebrovasdis.2007.10.006.
Agrawal RP, Sharma R, Garg D, Pokharna R, Kochar DK, Kothari RP. Role of Helicobacter pylori in causation of diabetic gastropathies and non-gastrointestinal complications in type 2 diabetes. J Indian Med Assoc. 2010;108(3):140–3. PMID: 21043350.
pubmed: 21043350
Wang F, Fu Y, Lv Z. Association of Helicobacter pylori infection with diabetic complications: a meta-analysis. Endocr Res. 2014;39(1):7–12. https://doi.org/10.3109/07435800.2013.794426 .
doi: 10.3109/07435800.2013.794426
pubmed: 23879556
Wang F, Liu J, Lv Z. Association of Helicobacter pylori infection with diabetes mellitus and diabetic nephropathy: a meta-analysis of 39 studies involving more than 20,000 participants. Scand J Infect Dis. 2013;45(12):930–8. https://doi.org/10.3109/00365548.2013.844351 .
doi: 10.3109/00365548.2013.844351
pubmed: 24143873
Zhou F, Zhong X, Chen J, Li C, Shang M, Jiang C, et al. Helicobacter pylori infection associated with type 2 diabetic nephropathy in patients with dyspeptic symptoms. Diabetes Res Clin Pract. 2015;110(3):328–34. https://doi.org/10.1016/j.diabres.2015.09.008 .
doi: 10.1016/j.diabres.2015.09.008
pubmed: 26547504
de Luis DA, de la Calle H, Roy G, de Argila CM, Valdezate S, Canton R, et al. Helicobacter pylori infection and insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1998;39(2):143–6. https://doi.org/10.1016/s0168-8227(97)00127-7 .
doi: 10.1016/s0168-8227(97)00127-7
pubmed: 9597384
Schimke K, Chubb SA, Davis WA, Davis TM. Helicobacter pylori cytotoxin-associated gene-A antibodies do not predict complications or death in type 2 diabetes: the Fremantle Diabetes Study. Atherosclerosis. 2010;212(1):321–6. https://doi.org/10.1016/j.atherosclerosis.2010.05.021 .
doi: 10.1016/j.atherosclerosis.2010.05.021
pubmed: 20839379
Pyo JH, Lee H, Choi SC, Cho SJ, Choi YH, Min YW, et al. Lack of Association between Past Helicobacter pylori infection and diabetes: a two-cohort study. Nutrients. 2019;11(8). https://doi.org/10.3390/nu11081874 .
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–53. https://doi.org/10.1002/(SICI)1096-9136(199807)15:7%3C;539::AID-DIA668%3E;3.0.CO;2-S .
Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37(10):2864–83. https://doi.org/10.2337/dc14-1296 .
doi: 10.2337/dc14-1296
pubmed: 25249672
pmcid: 4170131
American Diabetes Association Professional Practice C. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S185-S94. https://doi.org/10.2337/dc22-S012
Carmichael J, Fadavi H, Ishibashi F, Shore AC, Tavakoli M. Advances in screening, early diagnosis and Accurate Staging of Diabetic Neuropathy. Front Endocrinol (Lausanne). 2021;12:671257. https://doi.org/10.3389/fendo.2021.671257 .
doi: 10.3389/fendo.2021.671257
pubmed: 34122344
Chin JA, Sumpio BE. Diabetes mellitus and peripheral vascular disease: diagnosis and management. Clin Podiatr Med Surg. 2014;31(1):11–26. https://doi.org/10.1016/j.cpm.2013.09.001 .
doi: 10.1016/j.cpm.2013.09.001
pubmed: 24296015
Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: developing a diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022;28(10):923–1049. https://doi.org/10.1016/j.eprac.2022.08.002 .
doi: 10.1016/j.eprac.2022.08.002
pubmed: 35963508
pmcid: 10200071
Samsu N. Diabetic Nephropathy: challenges in Pathogenesis, diagnosis, and treatment. Biomed Res Int. 2021;2021:1497449. https://doi.org/10.1155/2021/1497449 .
doi: 10.1155/2021/1497449
pubmed: 34307650
pmcid: 8285185
Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Garcia-Perez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011;7(6):327–40. https://doi.org/10.4103/0366-6999.245269 .
doi: 10.4103/0366-6999.245269
pubmed: 21537349
Shi Y, Duan JY, Liu DW, Qiao YJ, Han QX, Pan SK, Helicobacter pylori Infection is Associated with Occurrence of Proteinuria in Type 2 Diabetes Patients: A Systemic Review and Meta-Analysis. Chin Med, Engl J et al.). https://doi.org/2018;131(22):2734-40. https://doi.org/10.4103/0366-6999.245269
Lim SH, Kim N, Kwon JW, Kim SE, Baik GH, Lee JY, et al. Positive Association between Helicobacter pylori Infection and metabolic syndrome in a Korean Population: a Multicenter Nationwide Study. Dig Dis Sci. 2019;64(8):2219–30. https://doi.org/10.1007/s10620-019-05544-3 .
doi: 10.1007/s10620-019-05544-3
pubmed: 30852768
King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol. 2008;79(8 Suppl):1527–34. https://doi.org/10.1902/jop.2008.080246 .
doi: 10.1902/jop.2008.080246
pubmed: 18673007
Esse R, Barroso M, Tavares de Almeida I, Castro R. The contribution of Homocysteine Metabolism disruption to endothelial dysfunction: state-of-the-art. Int J Mol Sci. 2019;20(4). https://doi.org/10.3390/ijms20040867 .
Cohen E, Levi A, Vecht-Lifshitz SE, Goldberg E, Garty M, Krause I. Assessment of a possible link between hyperhomocysteinemia and hyperuricemia. J Investig Med. 2015;63(3):534–8. https://doi.org/10.1097/JIM.0000000000000152 .
doi: 10.1097/JIM.0000000000000152
pubmed: 25646870
Lopes de Faria JB, Silva KC, Lopes de Faria JM. The contribution of hypertension to diabetic nephropathy and retinopathy: the role of inflammation and oxidative stress. Hypertens Res. 2011;34(4):413 – 22. https://doi.org/413-422.10.1038/hr.2010.263.
Chen M, Huang X, Gao M, Yang Z, Fang Z, Wei J, et al. Helicobacter pylori promotes inflammatory factor secretion and lung injury through VacA exotoxin-mediated activation of NF-kappaB signaling. Bioengineered. 2022;13(5):12760–71. https://doi.org/10.1080/21655979.2022.2071011 .
doi: 10.1080/21655979.2022.2071011
pubmed: 35603777
pmcid: 9275868
Kostov K, Blazhev A. Use of Glycated Hemoglobin (A1c) as a biomarker for vascular risk in type 2 diabetes: its relationship with Matrix Metalloproteinases-2, -9 and the metabolism of collagen IV and Elastin. Med (Kaunas). 2020;56(5). https://doi.org/10.3390/medicina56050231 .
Tommerdahl KL, Shapiro ALB, Nehus EJ, Bjornstad P. Early microvascular complications in type 1 and type 2 diabetes: recent developments and updates. Pediatr Nephrol. 2022;37(1):79–93. https://doi.org/10.1007/s00467-021-05050-7 .
doi: 10.1007/s00467-021-05050-7
pubmed: 33852054
Wan Z, Song L, Hu L, Hu M, Lei X, Huang Y, et al. Helicobacter pylori infection is associated with diabetes among Chinese adults. J Diabetes Investig. 2020;11(1):199–205. https://doi.org/10.1111/jdi.13102 .
doi: 10.1111/jdi.13102
pubmed: 31207188
Jeon CY, Haan MN, Cheng C, Clayton ER, Mayeda ER, Miller JW, et al. Helicobacter pylori infection is associated with an increased rate of diabetes. Diabetes Care. 2012;35(3):520–5. https://doi.org/10.2337/dc11-1043 .
doi: 10.2337/dc11-1043
pubmed: 22279028
pmcid: 3322696
Shi H, Li Y, Dong C, Si G, Xu Y, Peng M, et al. Helicobacter pylori infection and the progression of atherosclerosis: a systematic review and meta-analysis. Helicobacter. 2022;27(1):e12865. https://doi.org/10.1111/hel.12865 .
doi: 10.1111/hel.12865
pubmed: 34841620